Celldom

Executive Summary

Celldom, a San Francisco-based biotechnology company, has developed a pioneering live single-cell biology platform that enables real-time, high-throughput analysis of cellular morphology, phenotype, activity, and molecular profiles from individual cells under standard culture conditions. By quantifying cellular heterogeneity and dynamic cell behavior, the platform addresses critical bottlenecks in drug discovery and cell therapy development, offering researchers unprecedented insight into cell-to-cell variability that often underlies therapeutic resistance and efficacy. Founded in 2016, the company operates at the intersection of cell biology and artificial intelligence, leveraging machine learning to parse high-dimensional single-cell data. While still in a private stage with limited public financial disclosures, Celldom's technology holds promise for accelerating the identification of novel targets, optimizing cell therapy manufacturing, and enabling more predictive preclinical models. The platform's ability to monitor live cells non-invasively over time positions it as a potential enabling tool for both academic and industrial research. As the field of single-cell analysis continues to expand, Celldom's real-time approach could differentiate it from conventional endpoint assays, though commercial traction and clinical validation remain to be established.

Upcoming Catalysts (preview)

• Q2 2027Series A or Series B Funding Round70% success
• H2 2027Pharmaceutical Partnership for Drug Discovery60% success
• Q4 2026Publication of Validation Data in Peer-Reviewed Journal80% success